03/17/2017

Updates to the NCCN Templates® for Breast Cancer

The following updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) have been made to reflect the NCCN Guidelines for Breast Cancer, Version 1.2017.

• The following templates have been deleted:
  • BRS15a: FEC (Fluorouracil/EPIrubicin/Cyclophosphamide) followed by DOCEtaxel – FEC (Fluorouracil/EPIrubicin/Cyclophosphamide) courseo    BRS15b: FEC (Fluorouracil/EPIrubicin/Cyclophosphamide) followed by DOCEtaxel – DOCEtaxel course
  • BRS80a: FEC (Fluorouracil/EPIrubicin/Cyclophosphamide) Every 21 Days followed by PACLItaxel Weekly – FEC (Fluorouracil/EPIrubicin/Cyclophosphamide) course
  • BRS80b: FEC (Fluorouracil/EPIrubicin/Cyclophosphamide) Every 21 Days followed by PACLItaxel Weekly – PACLItaxel course
• Indications for the following templates have been changed to “Recurrent or Metastatic” (Neoadjuvant and Adjuvant settings were removed)
  • BRS1: FAC (Fluorouracil/DOXOrubicin/IV Cyclophosphamide)
  • BRS2: CAF (Oral Cyclophosphamide/DOXOrubicin/Fluorouracil)
  • BRS3: CEF (Oral Cyclophosphamide/EPIrubicin/Fluorouracil)

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium^®, the NCCN Biomarkers Compendium^®, the NCCN Templates^®, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.